How biopharma is scaling sterile manufacturing in 2026
As the demand for biologics accelerates, biopharma companies are under pressure to expand sterile manufacturing capacity quickly and reliably. But in 2026, a shifting geopolitical environment is forcing companies to rethink where capacity is built and scaled.
